Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study

KP. Dieckmann, T. Pokrivcak, L. Geczi, D. Niehaus, I. Dralle-Filiz, C. Matthies, T. Dienes, S. Zschäbitz, P. Paffenholz, T. Gschliesser, R. Pichler, M. Mego, P. Bader, F. Zengerling, J. Heinzelbecker, P. Krausewitz, S. Krege, G. Aurilio, C....

. 2022 ; 14 (-) : 17588359221086813. [pub] 20220331

Language English Country Great Britain

Document type Journal Article

Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population. Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively. Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate. Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.

2nd Department of Oncology Faculty of Medicine Comenius University Bratislava Slovak Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Masaryk University Brno Czech Republic

Department of Hematology and Oncology Red Cross Hospital Munich Germany

Department of Internal Medicine 2 Universitätsklinikum Krems Krems AustriaDepartment of Oncology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Medical Oncology Universitätsklinikum Heidelberg Heidelberg Germany

Department of Medical Oncology Wilhelminenspital Vienna Austria

Department of Oncology Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology Hematology and Bone Marrow Transplantation with Division of Pneumology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Urology Albertinen Krankenhaus Hamburg Germany

Department of Urology and Andrology Paracelsus Medical University Salzburg Salzburg Austria

Department of Urology and Pediatric Urology Universitätsklinikum Bonn Bonn Germany

Department of Urology and Pediatric Urology University Medical Centre Saarland University Homburg Saar Germany

Department of Urology Asklepios Klinik Altona Hamburg Germany

Department of Urology Bundeswehrkrankenhaus Hamburg Hamburg Germany

Department of Urology Bundeswehrkrankenhaus Ulm Ulm Germany

Department of Urology Bundeswehrzentralkrankenhaus Koblenz Koblenz Germany

Department of Urology Central Hospital Bolzano Bolzano Italy

Department of Urology Evangelische Kliniken Essen Mitte Essen Germany

Department of Urology Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Urology Hodentumorzentrum Asklepios Klinik Altona Paul Ehrlich Straße 1 22763 Hamburg Germany

Department of Urology Klinikum Klagenfurt Klagenfurt Austria

Department of Urology Medical University of Innsbruck Innsbruck Austria

Department of Urology Städtisches Klinikum Karlsruhe Karlsruhe Germany

Department of Urology Universitätsklinikum Halle Germany

Department of Urology Universitätsklinikum Schleswig Holstein Lübeck Germany

Department of Urology Universitätsklinikum Ulm Ulm Germany

Department of Urology Uro Oncology Robot Assisted and Reconstructive Urologic Surgery University Hospital Cologne Cologne Germany

Division of Oncology Medical University of Graz Graz Austria

Institute of Medical Biometry and Epidemiology University Medical Center Hamburg Eppendorf Hamburg Germany

Klinik und Poliklinik für Urologie Medizinische Fakultät Carl Gustav Carus Technische Universität Dresden Dresden Germany

Martini Klinik University Medical Center Hamburg Eppendorf Hamburg Germany

Medical Oncology Division of Urogenital and Head and Neck Tumours IEO European Institute of Oncology IRCCS Milan Italy

National Institute of Oncology Budapest Hungary

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017482
003      
CZ-PrNML
005      
20220720100238.0
007      
ta
008      
220718s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/17588359221086813 $2 doi
035    __
$a (PubMed)35386956
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dieckmann, Klaus-Peter $u Department of Urology, Hodentumorzentrum, Asklepios Klinik Altona, Paul Ehrlich Straße 1, 22763 Hamburg, Germany $1 https://orcid.org/0000000238217956
245    10
$a Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study / $c KP. Dieckmann, T. Pokrivcak, L. Geczi, D. Niehaus, I. Dralle-Filiz, C. Matthies, T. Dienes, S. Zschäbitz, P. Paffenholz, T. Gschliesser, R. Pichler, M. Mego, P. Bader, F. Zengerling, J. Heinzelbecker, P. Krausewitz, S. Krege, G. Aurilio, C. Aksoy, M. Hentrich, C. Seidel, P. Törzsök, T. Nestler, M. Majewski, A. Hiester, T. Buchler, S. Vallet, H. Studentova, S. Schönburg, D. Niedersüß-Beke, J. Ring, E. Trenti, A. Heidenreich, C. Wülfing, H. Isbarn, U. Pichlmeier, M. Pichler
520    9_
$a Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population. Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively. Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate. Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pokrivcak, Tomas $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
700    1_
$a Geczi, Lajos $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Niehaus, David $u Department of Urology, Asklepios Klinik Altona, Hamburg, Germany
700    1_
$a Dralle-Filiz, Inken $u Department of Urology, Albertinen-Krankenhaus, Hamburg, Germany
700    1_
$a Matthies, Cord $u Department of Urology, Bundeswehrkrankenhaus Hamburg, Hamburg, Germany
700    1_
$a Dienes, Tamas $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Zschäbitz, Stefanie $u Department of Medical Oncology, Universitätsklinikum Heidelberg, Heidelberg, Germany
700    1_
$a Paffenholz, Pia $u Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Cologne, Germany
700    1_
$a Gschliesser, Tanja $u Department of Urology, Klinikum Klagenfurt, Klagenfurt, Austria
700    1_
$a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Mego, Michal $u 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic
700    1_
$a Bader, Pia $u Department of Urology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
700    1_
$a Zengerling, Friedemann $u Department of Urology, Universitätsklinikum Ulm, Ulm, Germany
700    1_
$a Heinzelbecker, Julia $u Department of Urology and Pediatric Urology, University Medical Centre, Saarland University, Homburg/Saar, Germany
700    1_
$a Krausewitz, Philipp $u Department of Urology and Pediatric Urology, Universitätsklinikum Bonn, Bonn, Germany
700    1_
$a Krege, Susanne $u Department of Urology, Evangelische Kliniken Essen-Mitte, Essen, Germany
700    1_
$a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Aksoy, Cem $u Klinik und Poliklinik für Urologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Hentrich, Marcus $u Department of Hematology and Oncology, Red Cross Hospital, Munich, Germany
700    1_
$a Seidel, Christoph $u Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Törzsök, Péter $u Department of Urology and Andrology, Paracelsus Medical University Salzburg, Salzburg, Austria
700    1_
$a Nestler, Tim $u Department of Urology, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany
700    1_
$a Majewski, Matthaeus $u Department of Urology, Bundeswehrkrankenhaus Ulm, Ulm, Germany
700    1_
$a Hiester, Andreas $u Department of Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
700    1_
$a Buchler, Tomas $u Department of Oncology, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Vallet, Sonia $u Department of Internal Medicine II, Universitätsklinikum Krems, Krems, AustriaDepartment of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Studentova, Hana $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Schönburg, Sandra $u Department of Urology, Universitätsklinikum Halle (Saale), Halle (Saale), Germany
700    1_
$a Niedersüß-Beke, Dora $u Department of Medical Oncology, Wilhelminenspital, Vienna, Austria
700    1_
$a Ring, Julia $u Department of Urology, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
700    1_
$a Trenti, Emanuela $u Department of Urology, Central Hospital Bolzano, Bolzano, Italy
700    1_
$a Heidenreich, Axel $u Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Cologne, Germany
700    1_
$a Wülfing, Christian $u Department of Urology, Asklepios Klinik Altona, Hamburg, Germany
700    1_
$a Isbarn, Hendrik $u Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Pichlmeier, Uwe $u Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Pichler, Martin $u Division of Oncology, Medical University of Graz, Graz, Austria
773    0_
$w MED00177175 $t Therapeutic advances in medical oncology $x 1758-8340 $g Roč. 14, č. - (2022), s. 17588359221086813
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35386956 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100233 $b ABA008
999    __
$a ind $b bmc $g 1816606 $s 1168724
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c - $d 17588359221086813 $e 20220331 $i 1758-8340 $m Therapeutic advances in medical oncology $n Ther Adv Med Oncol $x MED00177175
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...